These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 15941028)

  • 1. Are SSRIs really more effective for anxious depression?
    Panzer MJ
    Ann Clin Psychiatry; 2005; 17(1):23-9. PubMed ID: 15941028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Care of depressed patients with anxiety symptoms.
    Nutt DJ
    J Clin Psychiatry; 1999; 60 Suppl 17():23-7; discussion 46-8. PubMed ID: 10446738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?
    Ribot R; Ouyang B; Kanner AM
    Epilepsy Behav; 2017 May; 70(Pt A):5-9. PubMed ID: 28407526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxious depression and response to treatment.
    Nelson JC
    Am J Psychiatry; 2008 Mar; 165(3):297-9. PubMed ID: 18316424
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
    Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of antidepressants currently used to treat anxiety disorders.
    Feighner JP
    J Clin Psychiatry; 1999; 60 Suppl 22():18-22. PubMed ID: 10634351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
    Zhang Y; Becker T; Ma Y; Koesters M
    BMC Psychiatry; 2014 Aug; 14():245. PubMed ID: 25159460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
    Finley PR
    Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
    Keller MB
    J Clin Psychiatry; 2000 Dec; 61(12):896-908. PubMed ID: 11206593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
    Walitt B; Urrútia G; Nishishinya MB; Cantrell SE; Häuser W
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011735. PubMed ID: 26046493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with depression associated with anxiety symptoms.
    Nutt D
    J Clin Psychiatry; 1997; 58 Suppl 8():11-6. PubMed ID: 9236730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
    Hayasaka Y; Purgato M; Magni LR; Ogawa Y; Takeshima N; Cipriani A; Barbui C; Leucht S; Furukawa TA
    J Affect Disord; 2015 Jul; 180():179-84. PubMed ID: 25911132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin and noradrenaline reuptake inhibitors: a step forward in the treatment of depression?].
    Möller HJ; Bauer M; Fritze J; Haen E; Laux G; Müller WE; Rüther E
    MMW Fortschr Med; 2005 Jan; 147(3):43-5. PubMed ID: 15727113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients.
    Filteau MJ; Baruch P; Lapierre YD; Bakish D; Blanchard A
    Int Clin Psychopharmacol; 1995 Mar; 10(1):51-4. PubMed ID: 7622805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does mirtazapine have a more rapid onset than SSRIs?
    Quitkin FM; Taylor BP; Kremer C
    J Clin Psychiatry; 2001 May; 62(5):358-61. PubMed ID: 11411818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.